

## Special Issue

# Advances in Integrins in Cancer

### Message from the Guest Editor

The integrin family of cell surface receptors mediate cell–extracellular matrix interactions in the vast majority of human cell types. Given their fundamental roles in normal development and healing, it is unsurprising that integrins also play significant roles in the development and progression of many types of cancer. Changes in integrin expression are common in cancers, allowing cells to migrate away from the original tumor site, establish metastases in specific organs, evade immune surveillance, and contribute to resistance to chemo-, radio-, and targeted therapy. This Special Issue will highlight recent progress in understanding the contributions of integrins to tumor biology, in addition to new technologies that target integrins in tumors and the tumor microenvironment.

### Guest Editor

Dr. Helen M. Sheldrake

Institute of Cancer Therapeutics, University of Bradford, Bradford, UK

### Deadline for manuscript submissions

closed (31 October 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/123542](https://mdpi.com/si/123542)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)